Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

Recruiting now · Not applicable

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.

Key facts

Study ID

NCT02965326

Run by

Hôpital Necker-Enfants Malades

People needed

75

Starts

2016-05-01

Expected to finish

2026-10-01

Last updated by the study team

2024-03-12

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cystic fibrosis patients treated by CFTR modulators (Ivacaftor or the association Ivacaftor-Lumacaftor)
• Cystic fibrosis patients non treated by CFTR modulators
• Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations

You may not qualify if…

• pregnant or lactating women
• contraindication to nasal swab
• contraindication to rectal biopsy

Where it is running

• Necker Hospital — Paris, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.